Savara Inc Payments of Financing Costs
Savara Inc (SVRA) reported Payments of Financing Costs of $50.00 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2017-05-09
- Savara Inc payments of financing costs for the quarter ending 2017-03-31 was $50.00K, a 31.58% increase year-over-year.
- Savara Inc payments of financing costs for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Savara Inc payments of financing costs for the quarter ending 2016-09-30 was $76.00K.
- Savara Inc payments of financing costs for the quarter ending 2016-06-30 was $9.00K.
- Savara Inc payments of financing costs for fiscal 2016 was $123.00K, a 36.27% decline from fiscal 2015.
- Savara Inc payments of financing costs for fiscal 2015 was $193.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2017-03-31 | $50.00K 10-Q · filed 2017-05-09 | $50.00K derived: sum of 2 quarters · filed 2017-05-09 | $126.00K derived: sum of 3 quarters · filed 2017-05-09 | $135.00K derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $76.00K derived: sum of 2 quarters · filed 2017-03-06 | $85.00K derived: sum of 3 quarters · filed 2017-03-06 | $123.00K 10-K · filed 2017-03-06 |
| 2016-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $85.00K derived: sum of 2 quarters · filed 2016-11-08 | $123.00K 10-Q · filed 2016-11-08 | $156.00K derived: sum of 4 quarters · filed 2017-05-09 |
| 2016-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $47.00K 10-Q · filed 2016-08-09 | $80.00K derived: sum of 3 quarters · filed 2017-05-09 | |
| 2016-03-31 | $38.00K 10-Q · filed 2017-05-09 | $71.00K derived: sum of 2 quarters · filed 2017-05-09 | ||
| 2015-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $193.00K 10-K · filed 2017-03-06 | ||
| 2015-09-30 | $160.00K 10-Q · filed 2016-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |